Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 23

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 23
---
 by paying to us an amount required
for us to receive its share of the Net Revenue on a quarterly basis.

Pursuant to the Gloperba License Agreement, the Licensee shall
obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion.

15

Promptly after the Effective Date, we are required to (i) facilitate an introduction
between the Licensee and our contract manufacturer of the Gloperba Product (the “Gloperba CMO”) as of the Effective Date, and (ii) use reasonable efforts to cause such Gloperba CMO to accept a direct engagement with the Licensee for
the manufacturing or supply of the Gloperba Product in finished dosage form. In addition, we agreed to appoint the Licensee as its exclusive distributor of the Gloperba Product in the entire world other than the United States during the Gloperba
License Term.

The term of the Gloperba License Agreement commences on the Effective Date and continues until expiration of the last to
expire Licensed Patents (as defined therein), unless earlier terminated (the “Gloperba License Term”).

Bid Price Deficiency & Reverse Split

On November 1, 2024, we received a letter (the “Notice”) from Nasdaq notifying the Company that,
because the closing bid price for its Common Stock has been below $1.00 per share for 30 consecutive business days, it did not comply with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule
5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists
if the deficiency continues for a period of 30 consecutive business days. The Notice also indicated that the Company had 180 calendar days, or until April 30, 2025 (the “Compliance Period”), to regain compliance pursuant to Nasdaq
Listing Rule 5810(c)(3)(A).

On March 19, 2025 at a special meeting of our stockholders, our stockholders approved the amendment of
our Certificate of Incorporation to effect a reverse stock split within a range of 1-for-14 to
1-for-50, with such ratio to be determined ultimately by the Board